艾昆纬(IQVIA)集团10月31日在盘前交易中出现大涨7.87%的情况,引起了市场广泛关注。公司传来的消息或为此股价暴跌带来合理解释。
IQVIA是一家为生物技术和制药公司提供临床研究服务的合同研究机构。在当前财报发布中,公司下调了2024年度的收入和盈利预期。此前公司预计2024年收入将在154.3亿至155.3亿美元区间,现在下调至153.5亿至154亿美元。调整后每股收益预估上限也从11.30美元下调至11.20美元。
公司表示,导致此次下调预期的主要原因是其一名客户面临物流挑战,导致两项临床试验被延期。临床试验的延误带来了营收的延迟,影响了公司原有的财务指引。投资者对公司前景信心下降,可能是当日股价大跌的主要因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.